# A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

> **NCT04895241** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Biogen** · enrollment: 548 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Litifilimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04895241
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-25
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-03-16
- **Target enrollment:** 548 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04895241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04895241, "A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04895241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*